Stockholders' Equity - Additional Information (Detail) - USD ($)
|
|
|
|
|
|
1 Months Ended |
3 Months Ended |
12 Months Ended |
|
|
|
|
Oct. 13, 2015 |
Jul. 15, 2015 |
Jun. 01, 2015 |
Nov. 06, 2014 |
Jun. 02, 2014 |
Dec. 02, 2015 |
Sep. 18, 2015 |
Aug. 31, 2015 |
Jul. 28, 2015 |
Dec. 01, 2014 |
Dec. 02, 2013 |
Jun. 30, 2013 |
May. 31, 2013 |
Mar. 31, 2015 |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2013 |
Oct. 19, 2015 |
Jun. 02, 2015 |
Dec. 02, 2014 |
Mar. 17, 2014 |
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock Based compensation, Options Contractual term |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10 years
|
|
|
|
|
|
|
| Stock-based compensation weighted-average vesting period |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 month 6 days
|
|
|
|
|
|
|
| Employee Stock Purchase Plan to eligible employees, Reckoning fair value percentage during offering period |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
85.00%
|
|
|
|
|
|
|
| Employee Stock Purchase Plan to eligible employees, compensation expense recognized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 27,000
|
$ 25,000
|
$ 46,000
|
|
|
|
|
| Share Based Compensation Restricted Stock Units |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 6,900,000
|
$ 4,000,000
|
66,000
|
|
|
|
|
| Common Stock Par Or Stated Value Per Share |
|
|
|
|
|
|
$ 0.0001
|
|
|
|
|
|
|
|
$ 0.001
|
$ 0.001
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 11,600,000
|
|
|
|
|
|
| Share Price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2.93
|
|
|
|
|
|
|
| Research And Development Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 18,402,000
|
10,239,000
|
25,682,000
|
|
|
|
|
| General And Administrative Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21,584,000
|
10,413,000
|
10,098,000
|
|
|
|
|
| Allocated Share-based Compensation Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,000,000
|
$ 3,300,000
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,660,280
|
|
|
|
|
|
|
| Fair Value Assumptions, Weighted Average Volatility Rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25.60%
|
|
|
|
|
|
|
| Proceeds from Stock Options Exercised |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 216,000
|
596,000
|
970,000
|
|
|
|
|
| Fair Value Assumption Historical Volatility Rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
80.00%
|
|
|
|
|
|
|
| Fair Value Assumptions Implied Volatility Rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20.00%
|
|
|
|
|
|
|
| Class of Warrant or Right, Exercise Price of Warrants or Rights |
|
|
|
|
|
|
$ 7.00
|
|
|
|
|
|
|
|
$ 2,500
|
|
|
|
|
|
|
| Stock Issued During Period, Value, Issued for Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,000
|
4,000
|
4,000
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross |
|
|
|
|
|
|
|
|
|
|
|
|
|
1,500,000
|
0
|
|
|
|
|
|
|
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7.00
|
|
|
|
|
|
|
| Fair Value Assumptions, Risk Free Interest Rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.10%
|
|
|
|
|
|
|
| Proceeds from issuance of Common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
3,502,000
|
91,337,000
|
|
|
|
|
| Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,700,000
|
|
|
|
|
|
|
| Share-based Compensation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 14,291,000
|
5,546,000
|
5,902,000
|
|
|
|
|
| Percentage Of Placement Agent Fee |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.00%
|
|
|
|
|
|
|
| Proceeds from Issuance of Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 57,800,000
|
|
|
|
|
|
|
| Net Proceeds From Issuance Of Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 51,500,000
|
|
|
|
|
|
|
| Stock Issued For Exercise Of Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000
|
|
|
|
|
|
|
| Warrant Purchase Price Per Unit |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 50,000
|
|
|
|
|
|
|
| Stock Issued During Period Shares warrants Exercised |
|
|
|
|
|
|
2,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock Issued During Period, Shares, New Issues |
|
|
|
|
|
|
10,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock Issued During Period, Value of Warrants Excercised |
|
|
|
|
|
|
$ 50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Equity Method Investment, Ownership Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
35.00%
|
| Plan 2013 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock Based compensation, shares available for issuance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,339,720
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,300,000
|
|
|
|
|
|
|
| Plan 2007 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,000,000
|
|
|
|
|
|
|
| Lindsay A Rosenwald [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Price |
|
|
|
$ 1.61
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| After Amendment [Member] | Convertible Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.001
|
|
|
|
|
|
|
| Capital Units, Authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,000,000
|
|
|
|
|
|
|
| After Amendment [Member] | Convertible Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.001
|
|
|
|
|
|
|
| Capital Units, Authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000,000
|
|
|
|
|
|
|
| Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000,000
|
|
|
|
|
|
|
| Chief Executive Officer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock Issued During Period, Shares, Issued for Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,000,000
|
|
|
|
|
|
|
| Mr. George Avgerinos [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized |
|
|
|
2,175,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Former Board Of Director [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Restricted Stock Units |
|
$ 133,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dr. Rosenwald [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from issuance of Common stock |
|
|
|
$ 3,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized |
|
|
|
2,175,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mr. Weiss [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized |
|
|
|
2,175,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Senior Vice President [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage |
|
50.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock Issued During Period, Value, Issued for Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,900,000
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross |
|
|
|
|
|
|
|
|
|
|
|
200,000
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost |
|
$ 3,700,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Director [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage |
|
25.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Avenue Therapeutics, Inc. [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Research And Development Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21,000
|
|
|
|
|
|
|
| General And Administrative Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29,000
|
|
|
|
|
|
|
| Allocated Share-based Compensation Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 50,400
|
|
|
|
|
|
|
| Weighted Market Value Percentage of Invested Capital |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
44.80%
|
|
|
|
|
|
|
| Weighted Average Cost Percentage of Capital |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.00%
|
|
|
|
|
|
|
| Shares Issued, Price Per Share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.146
|
|
|
|
|
|
|
| Avenue Therapeutics, Inc. [Member] | Consultants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Research And Development Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 21,000
|
|
|
|
|
|
|
| Stock Issued During Period, Shares, Issued for Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
150,000
|
|
|
|
|
|
|
| Avenue Therapeutics, Inc. [Member] | Chief Executive Officer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock Issued During Period, Shares, Issued for Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,000,000
|
|
|
|
|
|
|
| Avenue Therapeutics, Inc. [Member] | Share-based Compensation Award, Tranche One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50.00%
|
|
|
|
|
|
|
| Avenue Therapeutics, Inc. [Member] | Share-based Compensation Award, Tranche Two [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.50%
|
|
|
|
|
|
|
| Avenue Therapeutics, Inc. [Member] | Share-based Compensation Award, Tranche Three [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50.00%
|
|
|
|
|
|
|
| Journey Medical Corporation [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Price |
|
|
|
|
|
|
|
|
$ 0.65
|
|
|
|
|
|
|
|
|
|
|
|
|
| General And Administrative Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 597,000
|
|
|
|
|
|
|
| Weighted Market Value Percentage of Invested Capital |
|
|
|
|
|
|
|
|
44.50%
|
|
|
|
|
|
|
|
|
|
|
|
|
| Weighted Average Cost Percentage of Capital |
|
|
|
|
|
|
|
|
30.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross |
|
|
|
|
|
|
|
|
1,950,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,250,000
|
|
|
|
| Unamortized Debt Issuance Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 800,000
|
|
|
|
| Checkpoint Therapeutics, Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Price |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.065
|
$ 4.39
|
|
|
|
|
|
|
| Research And Development Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4.39
|
|
|
|
|
|
|
| Fair Value Assumptions, Weighted Average Volatility Rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
30.00%
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
25.00%
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period |
|
|
|
|
|
|
|
|
|
|
|
|
|
48 months
|
|
|
|
|
|
|
|
| Weighted Average Cost Percentage of Capital |
|
|
|
|
|
|
|
|
|
|
|
|
|
44.80%
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights |
|
|
|
|
|
|
|
0.129
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair Value Assumptions, Risk Free Interest Rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
83.00%
|
|
|
|
|
|
|
| Number Of Warrants Granted On Common Stock For Services |
|
|
|
|
|
|
|
100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Marketability Percentage Of Invested Capital |
|
|
|
|
|
|
|
44.10%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage Of Weighted Average Cost Of Capital |
|
|
|
|
|
|
|
30.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Equity Method Investment, Ownership Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37.70%
|
|
|
|
|
|
|
| Checkpoint Therapeutics, Inc [Member] | Chief Executive Officer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate |
83.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate |
1.50%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Price |
$ 4.39
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation |
$ 265,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Checkpoint Therapeutics, Inc [Member] | Chief Executive Officer [Member] | Installments One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Achievement Of Fully Diluted Market Capitalizations Value |
$ 250,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Achievement Of Fully Diluted Market Capitalizations Common Stock Per Share |
$ 4.26
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Checkpoint Therapeutics, Inc [Member] | Chief Executive Officer [Member] | Installments Two [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Achievement Of Fully Diluted Market Capitalizations Value |
$ 500,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Achievement Of Fully Diluted Market Capitalizations Common Stock Per Share |
$ 3.89
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Checkpoint Therapeutics, Inc [Member] | Chief Executive Officer [Member] | Installments Three [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Achievement Of Fully Diluted Market Capitalizations Value |
$ 750,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Achievement Of Fully Diluted Market Capitalizations Common Stock Per Share |
$ 3.64
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| JMC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Allocated Share-based Compensation Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 597,000
|
|
|
|
|
|
|
| Research and Development Expense [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Allocated Share-based Compensation Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,800,000
|
1,100,000
|
3,000,000
|
|
|
|
|
| Research and Development Expense [Member] | Checkpoint Therapeutics, Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation |
|
|
|
|
|
|
|
$ 13,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| General and Administrative Expense [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Allocated Share-based Compensation Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,500,000
|
4,400,000
|
$ 2,900,000
|
|
|
|
|
| Restricted Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Restricted Stock Units |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
400,000
|
4,343,692
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1.3
|
|
|
|
|
|
|
| Deferred Compensation Arrangement with Individual, Shares Issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
290,000
|
|
|
|
|
|
|
| Restricted Stock [Member] | Checkpoint Therapeutics, Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total |
1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Restricted Stock Units (RSUs) [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock-based compensation weighted-average vesting period |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 year 8 months 12 days
|
|
|
|
|
|
|
| Share Based Compensation Restricted Stock Units |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,600,000
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross |
|
40,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5,000,000
|
|
|
|
|
|
|
| Restricted Stock Units (RSUs) [Member] | Senior Vice President [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross |
|
1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
300,000
|
|
|
|
|
|
|
| Restricted Stock Units (RSUs) [Member] | Director [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross |
|
50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| New Award [Member] | Senior Vice President [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost |
|
$ 3,300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Old Award [Member] | Senior Vice President [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost |
|
$ 400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Employee Stock Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Based Compensation Arrangement By Share Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Employee Stock Purchase Plan to eligible employees, Reckoning fair value percentage during offering period |
|
|
|
|
85.00%
|
85.00%
|
|
|
|
|
85.00%
|
|
85.00%
|
|
|
|
|
|
85.00%
|
85.00%
|
|
| Common Stock issued in connection with the first ESPP offering |
|
|
14,681
|
|
7,139
|
13,317
|
|
|
|
6,841
|
6,065
|
|
21,505
|
|
91,192
|
|
|
|
|
|
|
| Common Stock Par Or Stated Value Per Share |
|
|
|
|
$ 1.45
|
$ 2.41
|
|
|
|
|
$ 1.39
|
|
$ 3.88
|
|
|
|
|
|
$ 1.80
|
$ 1.80
|
|
| Share Price |
|
|
|
|
$ 1.71
|
$ 2.84
|
|
|
|
$ 2.12
|
$ 1.64
|
|
$ 4.56
|
|
|
|
|
|
$ 2.12
|
|
|
| Proceeds from Stock Options Exercised |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 200,000
|
$ 600,000
|
|
|
|
|
|
| Common Stock, Capital Shares Reserved for Future Issuance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
108,808
|
|
|
|
|
|
|